Research programme: small glycanic drugs - Endotis

Drug Profile

Research programme: small glycanic drugs - Endotis

Alternative Names: EP 30; EP 31; EP 32; EP 33; EP 80061; EP8000; Small glycanic drugs research programme - Endotis

Latest Information Update: 03 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Endotis Pharma
  • Class Oligosaccharides
  • Mechanism of Action Chemokine receptor antagonists; Intercellular signalling peptide and protein inhibitors; Interferon gamma inhibitors; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer; Inflammatory bowel diseases; Multiple sclerosis; Rheumatoid arthritis; Solid tumours

Most Recent Events

  • 02 Mar 2011 Preclinical development in Solid tumours is ongoing in France
  • 01 Jan 2011 Preclinical trials in Cancer in France (Parenteral)
  • 17 Apr 2010 Pharmacodynamics data from preclinical studies in Solid tumours presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR-2010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top